Loading market dashboard
Catalyst Pharmaceuticals, Inc.
CPRXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.68 per share a year ago.
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) related to its sale to Angelini Pharma S.p.A. Under the terms of the proposed transaction Catalyst shareholders are expected to receive $31.50 per share in cash. Is it a fair deal?
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led to it.
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A.
Get a deeper insight into the potential performance of Catalyst (CPRX) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
MILWAUKEE , May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Catalyst (NASDAQ: CPRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Angelini Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash.Halper Sadeh encourages Catalyst shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Catalyst and its board of dir.
The move marks Italy's Angelini Pharma's entry into the U.S. market.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla. , May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.
Italy's Angelini Pharma said on Thursday it has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion.
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta
The mean of analysts' price targets for Catalyst (CPRX) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022's first outlier institutional inflow signal.
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
EFXT, CPRX, GEV, STRA and BP have been added to the Zacks Rank #1 (Strong Buy) List on March 31st, 2026.
CPRX, STRT and BP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 31st, 2026.
The mean of analysts' price targets for Catalyst (CPRX) points to a 45.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the best option for those looking for undervalued stocks?
Catalyst Pharmaceuticals (NASDAQ: CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Daly also reviewed early commercial progress for Agamree in Duchenne muscular dystrophy (DMD), provided an update
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Market volatility is reviving value hunts. AL, NESR, CPRX and JBTM stand out with low PEG metrics and solid growth outlooks after passing strict value screens.
Choreo LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,895 shares of the biopharmaceutical company's stock, valued at approximately $412,000. Other large investors also recently made changes to
